1. Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations

3. Introduction/Background

4. Pathophysiology and Progression of SLE

5. Common Lupus Symptoms

6. Global Prevalence of SLE

7. Comorbidities Associated With SLE

8. Sensitivity, Specificity of Selected Criteria for SLE: SLICC Classification

9. Unmet Needs in the Management of SLE

10. SLE: Therapeutic Goals and the Treat-To-Target Approach

11. Why Has It Been So Hard to Develop New Therapies for SLE?

12. BSR Guidelines for the Management of SLE: Treatment Strategies

13. Guidelines Standard of Care and the Use of Targeted Therapies for SLE

14. Efficacy and Safety Results for Belimumab in SLE: BLISS-52

15. Efficacy and Safety Results for Belimumab in SLE: BLISS-76

16. SLE Concomitant Treatment With Belimumab and Rituximab: Phase 2A Trial Results

17. New and Emerging Therapies for SLE

18. Anifrolumab for the Treatment of SLE: Results From a Phase 2b Trial

19. Ustekinumab for the Treatment of SLE: Results From a Phase 2 Trial

20. Baricitinib for the Treatment of SLE: Results From a Phase 2 Trial

21. Summary and Conclusions

22. Abbreviations

23. Abbreviations (cont)